Meet the team of scientists and innovators who are working every day to help you synchronize with life!
InventaSpheres®
Our micro-pellets retain a core substance for up to 7-8 hours before releasing it into the body. InventaSpheres® are very different from traditional release profiles. Furthermore, they were proven in the market with our 1st product B・SYNC® ON, & in a double blinded placebo controlled clinical trial. As a platform, the technology can be applied to a number of indications.
Proven drug dynamics
Delayed drug release
Release during sleep
Absorption in the large intestine
Increase patient convenience and timing
Our innovative formulation (the way we coat the pellets in B・SYNC ON) is patented and we look forward to using this technology in more products in the future.
PATENTInner core:
The inert core, microcrys- talline cellulose pellets, is coated with caffeine to produce caffeine micropellets
Polymer coating:
The caffeine micropellets are coated with a polymeric system to provide a pulsatile release
Film Coating:
The micropellets are protected by additional film layers
Encapsulation:
The finished micropellets are packed in an HPMC capsule
InventaCarriers®
Ultra rapid disintegration system based on tricalcium phosphate. Galvita Templated Inverted Particles (Inventacarriers) are based on microcapsules that can be loaded with active ingredients and can be compressed to tablets with excellent mechanical strength, based on 100% natural inorganic material. Tested in the market with B・SYNC OFF, the tablets are tasteless, enable ultra-rapid disintegration without water, fast direct action & high bioavailability.
Rapid disintegration of the tablet
Good loading properties
Sensational taste masking
Fully natural / biodegradable
A paradigm shift in formulation development for ODT.
The technology is already being used successfully with over 20 active ingredients.
PATENTEDActivation
Calcination
Leaching
loading
Tableting
Our experts
Dr. Dario Dornbierer
CSODario is a pharmaceutical scientist (ETH Zurich), Swiss Federal pharmacist and...
Dr. Michael Bavand
Portfolio AdvisorMichael has studied chemistry and biology, and has a PhD from ETH Zurich...
Dr. Firat Yerlikaya
Chief Technology OfficerFirat holds a Master and Doctorate Degrees in Pharmaceutical Technology...
Dario Dornbierer is a pharmaceutical scientist (ETH Zurich), Swiss Federal pharmacist and clinical psychopharmacologist who specializes in drug development in mental health. After a residency year in a Swiss pharmacy, Dario conducted a PhD in the field of clinical psychopharmacology at the Psychiatric University Hospital in Zurich, where he investigated the antidepressant potential of several drug candidates, applying state-of-the-art neuroscientific methods (EEG , MRI, etc.). With a special focus on sleep pharmacology, he investigated the ability of several compounds to promote deep sleep and improve overall sleeping and waking functions. In his role as CSO, Dario is responsible for all aspects related to clinical sciences and innovation. Dario is passionate about the intricate interplay between the brain and the mind and how chemical substances can dramatically change the way we perceive the outer and inner world. As a pharmacist, I find it exciting to apply cutting-edge technologies to improve the safety, tolerability and efficacy of products. Dario is passionate about spending time with his wife and two kids, gardening and playing various instruments.
Michael has studied chemistry and biology with a Ph.D. from ETH Zurich. He has significant experience from previous R&D roles at leading industrial Life Science organizations in metabolic and cardiovascular health. A serial entrepreneur, Michael has led several start-up companies to profitability, including Siegfried Biologics, Kuros Biosciences and ChromaCon. Besides his assignment with Galventa, Michael is engaged in helping a Venture boutique company, Remora Capital to launch new start-up companies in the field of Cancer/Immunology and Healthy Aging. Having a specific interest in nutraceuticals and healthy aging, Michael works on developing new products, focusing on manufacturing, regulatory and quality issues. Michael supports organizations for disabled children and likes to meet his friends and extended family members to celebrate occasions as they occur. Michael enjoys studying art and history of late antiquity and is fond of classical music.
Michael holds a Master of Science in Molecular Health Science and a PhD in Neuroscience from the ETH Zurich. He specializes in the impact of nutrition and pharmacological substances on health and prevention of chronic diseases and is passionate about the ongoing research and new insights in the supplement industry. During his doctorate, Michael has investigated the clinical potential of new substances for treating psychological disorders, such as depression and anxiety. In his role as Product Development Lead at the B·SYNC parent company, Galventa, Michael is responsible for developing new products based on the latest scientific data. Michael is passionate about living a healthy lifestyle and has been a biohacker for many years, following scientific insight that small, incremental changes to his diet and supplementation can enhance his overall health and performance. “I have always dreamed of working within the supplement industry and I am enjoying applying the knowledge and insight gained from my Masters and PHD studies to creating new products at Galventa, and to being part of an exciting start-up initiative.” Outside of work, Michael enjoys meeting his friends, and going to the gym.
Dr Fırat Yerlikaya has previously founded Elixir Pharmaceutical Research and Development Corporation in Ankara, Turkey where he had been working as the Managing Director until he joined Galventa. He comes with a Master's and Doctorate Degrees in Pharmaceutical Technology and previous tenures in Washington DC, where he was invited to the US FDA as an ORISE fellow. Fırat continues his scientific studies with the development of complex pharmaceutical formulations and processes using quality-by-design and chemometric models. At B・SYNC ON parent company, Galventa, Fırat is responsible for supporting the development of formulations, manufacturing processes, scale-up and technology transfer studies, as well as providing analytical methodology and insights. Outside of his academic studies and work, Fırat is a passionate sailor, and enjoys sailing in the seas where Galenos used to live. He also enjoys fine whiskey and good food with his family and friends.
Dr Aslihan Arslan is an Award-winning Pharmaceutical Technologist, responsible for managing and leading the development of formulations, manufacturing processes, scale-up and technology transfer studies. Dr Arslan completed her Ph.D in Pharmaceutical Technology, writing a thesis on innovative scientific procedures for increasing the solubility and bioavailability of pharmaceutical compounds and substances using quality-by-design. In her role as Scientific Advisor at B・SYNC ON parent company, Galventa, Dr Arslan is responsible for the development and manufacturing of B・SYNC ON. Outside of her work, Dr Arslan is a devotee of the outdoors with a passion for everything under the sky, including nature, trekking, cross-country skiing, snowboarding and roller skating. She also enjoys photography.
Committed to science
We've nailed waking up and feeling good down to a science